Inhibitory effect of TRK-530 on inflammatory cytokines in bone marrow of rats with adjuvant arthritis.
TRK-530 is a novel synthetic bisphosphonate compound which exhibits inhibitory activity in the rat adjuvant arthritis (AA) model. We found that, during AA development, the concentrations of cytokine-induced neutrophil chemoattractant-1 (CINC-1) and tumor necrosis factor alpha (TNF-alpha) in the bone marrow increased, and that administration of TRK-530 decreased the concentrations of these cytokines. The suppression of these concentration increases paralleled the inhibition of paw edema. Paw edema inhibition by TRK-530 in rat AA may be the result of decreasing CINC-1 and TNF-alpha concentrations.
Tanahashi
M
M
Basic Research Laboratories, Toray Industries, Inc., Kanagawa, Japan. tanahash@blab.toray.co.jp
Koike
J
J
Kawabe
N
N
Nakadate-Matsushita
T
T
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001169:Arthritis, Experimental / Q000378:metabolism*; D001853:Bone Marrow / Q000187:drug effects / Q000378:metabolism*; D054360:Chemokine CXCL1; D019743:Chemokines, CXC / Q000378:metabolism; D002630:Chemotactic Factors / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism*; D004164:Diphosphonates / Q000494:pharmacology*; D005260:Female; D005528:Foot / Q000473:pathology; D006133:Growth Substances / Q000378:metabolism; D007249:Inflammation / Q000378:metabolism*; D036341:Intercellular Signaling Peptides and Proteins; D051381:Rats; D011917:Rats, Inbred Lew; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D054360:Chemokine CXCL1; D019743:Chemokines, CXC; D002630:Chemotactic Factors; C513297:Cxcl1 protein, rat; D016207:Cytokines; D004164:Diphosphonates; D006133:Growth Substances; D036341:Intercellular Signaling Peptides and Proteins; C109548:TRK 530; D014409:Tumor Necrosis Factor-alpha